Birt-Hogg-Dubé (BHD) syndrome, is a dominantly inherited familial cancer syndrome associated with susceptibility to renal cell carcinoma (RCC) caused by inactivating mutations in the folliculin (FLCN) gene. The precise functions of the FLCN gene product are still under investigation but RCC from BHD patients show loss of the wild-type allele consistent with a tumor suppressor gene function. In a search for potential synthetic-lethal targets for FLCN using a phosphatase siRNA library screening approach, we found that knockdown of SSH2 serine phosphatase (one of the three members of Slingshot family and previously implicated in actin reorganization) specifically induced Caspase3/7 activity in a dose-dependent manner (up to six-fold increase, 10 nM, 72 h) in two human FLCN-deficient cell lines (BHD-origin renal cell carcinoma UOK257 and thyroid carcinoma FTC133) but not in their folliculin expressing isogenic cell lines. SSH2 siRNA-induced knockdown was accompanied by increased expression of SSH1 and SSH3 (suggesting a compensatory regulatory mechanism among members of SSH family). FLCN-null cells exhibited evidence of dysregulated cofilin de/phosphorylation pathways. Knockdown of SSH2 in FLCN-null cells was associated with an alteration in cell cycle kinetics (20% increase in G1, 30% and 40% decrease in S and G2M, respectively). Combination treatment of multiple SSH family (SSH2 plus SSH1 and/or SSH3) siRNAs potentiated induction of Caspase3/7 activity and changes in the cell cycle kinetics. These data indicate that: (a) apoptotic cell death in FLCN-null cells can be triggered by SSH2 knockdown through cell cycle arrest; (b) SSH2 represents a potential therapeutic target for the development of agents for the treatment of BHD syndrome and, possibly, related tumors.
INTRODUCTION
Though familial forms of renal cell carcinoma (RCC) account for only o5% of all cases, genetic investigations of rare inherited forms of RCC have provided seminal insights into the molecular pathogenesis of both familial and sporadic RCC. This is exemplified by von Hippel-Lindau (VHL) disease (a dominantly inherited multisystem familial cancer syndrome associated clear cell RCC) as somatic inactivation of the VHL tumor suppressor gene (TSG) is the most frequent event in the evolution of sporadic clear cell RCC (cRCC). [1] [2] [3] [4] Subsequent studies demonstrated that inactivation of the VHL TSG was associated with dysregulation of the HIF-1 and HIF-2 transcription factors and activation of hypoxiaresponsive gene pathways and these findings provided a rationale for the use of drugs such as sorafenib and sunitinib (inhibitors of HIF target gene pathways) for the treatment of metastatic RCC. 5, 6 Birt-Hogg-Dubé (BHD) syndrome, is another dominantly familial cancer syndrome associated with susceptibility to RCC (and also benign skin fibrofolliculomas, multiple lung cysts and spontaneous pneumothrorax) 7, 8 and results from inactivating mutations in the folliculin (FLCN) gene. [9] [10] [11] The precise functions of the FLCN gene product are still under investigation but RCC from BHD patients show loss of the wild-type allele consistent with a TSG function. 12 In mice, homozygous inactivation of Flcn in the kidneys was associated with the development of renal tumors and cysts that demonstrated evidence of mTOR activation and the mTOR inhibitor rapamycin diminished kidney pathology and increased survival. 13, 14 A variety of strategies can be implemented to develop novel targeted therapies for human cancers. The synthetic lethality strategy seeks to identify those genes (called synthetic lethal genes) essential to cancer cells with a specific genotype such that loss of these genes in the presence of the specific cancer gene mutation will induce cancer cell death, but cells not harboring the specific cancer gene mutation will be unaffected. For example, in breast cancer cells with mutant BRCA1/2 (deficiency of DNA repair by homologous recombination), inhibition of PARP1 activity leads to an accumulation of single strand breaks that are converted to double strand breaks but cannot be repaired by homologous recombination. 15 This strategy has been successfully used in clinical trial with PARP1 inhibitors in treatment of breast cancer patients with BRCA1/2 mutation. 16, 17 In order to develop novel therapeutic approaches for BHD patients, we adopted a strategy to identify potential synthetic-lethality interactions by knockdown of specific phosphatases in a RCC cell line with FLCN inactivation. 1 
RESULTS
Selection of candidate genes by screening a phosphatase siRNA library in UOK257 renal cancer cell line with the loss of folliculin expression Screening of a siRNA library for 298 human phosphatase genes was undertaken in the folliculin-deficient (UOK257-FLCN null ) renal cell carcinoma cell line derived from a patient with BHD syndrome that harbors a germline FLCN frameshift mutation (c.1285dupC) (predicted, in the absence of nonsense-mediated mRNA decay, to lead to premature protein truncation (p.His429ProfsX27),.
18
UOK257-FLCN null cells were examined for their cellular viability after transfection with siRNAs for phosphatase or for luciferase control at 20 nM for 72 h as shown in Figure 1a . Three siRNAs were available for each phosphatase gene. The ratio of cell viability from phosphatase siRNA vs control siRNA were calculated and used as indicators for the sensitivity to mutant FLCN cells (o1). The potential positive hits identified by the lower ratio of cell viability (cutoff point p0.9) were selected from at least two of the three siRNAs for each gene (Figure 1b) . After first round screen, 34 genes were selected for the subsequent screening for dosedependent reduction in cell viability and dose-dependent increase in Caspase3/7 activity in UOK257-FLCN null cells. As shown in Figures 1c and d , knockdown of 34 genes showed broad variations in cell viability and Caspase3/7 activity in the second round screen in UOK257-FLCN null cells. However, knockdown of Slingshot phosphatases (SSH2 and SSH3, as numbered 14 and 16, respectively) met the criteria for potential positive hits with over two-fold increase in Caspase3/7 activity and decrease in cell viability (upto 40%).
Identification of SSH2 as a synthetic-lethal candidate target for folliculin-deficient cancer cell lines Slingshot phosphatases belong to a gene family of three members (SSH1, SSH2 and SSH3). Further detailed investigation with knockdown of individual gene of this family was undertaken in two pairs of isogenic FLCN null and FLCN þ cell lines (UOK257 and FTC133 a human thyroid carcinoma). SSH2 knockdown preferentially induced Caspase3/7 activity (up to seven-fold, 20 nM, 72 h) in UOK257-FLCN null cells when compared with that in matched UOK257-2-FLCN þ cells (one to two-fold; see Figure 2a ). Although there are three members in this family and SSH3 knockdown was initially selected as potential positive hit in the second round siRNA library screen, only SSH2 knockdown induced dosedependent increase in Caspase3/7 activity and resulted in dosedependent reduction in cell viability in UOK257 cells with mutant FLCN (Figure 2a) . Similar results for the preferential induction of Caspase3/7 activity were observed with SSH2 siRNA treatment in FTC133-12 cell line without FLCN expression (Figure 2b ). Although SSH2 knockdown induced a small increase (up to two-fold) in Caspase3/7 activity in FLCN-expressing FTC133-22 cells, in contrast to FTC133-FLCN null cells, the viability of these cells were unaltered. A time course of examination of the induction of Caspase3 activity in UOK257 cells was carried out and it found out that Caspase3/7 activation trigged by SSH2 knockdown did not occur until after 24 h and peaked at 72 h (five-fold, 20 nM, Figure 2c ). The induction of Caspase3/7 activity lasted for 6 days incubation of siRNA with UOK257-FLCN null cells but at a reduced rate (2.5-fold, 20 nM, data not shown).
Validation of SSH2 knockdown by real-time PCR and examination of cofilin and the relative proteins expression To validate the specificity of SSH2 knockdown in FTC133 cells, the transcript levels of SSH1, SSH2 and SSH3 were studied by real-time PCR. As shown in Figure 3a , SSH2 transcripts levels were reduced by B60% at the concentrations of 5 and 10 nM of SSH2 siRNA treatment for 72 h in both FTC133-12 (FLCN null ) and FTC133-22 (FLCN þ ) cells when compared with luciferase siRNA control.
In contrast, knockdown of SSH2 was accompanied by increased expression of SSH1 (up to 200%) and SSH3 (up to 130%), indicating a compensatory regulation mechanism of SSH gene family members. Previously, the Slingshot family of phosphatases has been demonstrated to have a crucial role in regulating the activity of cofilin, which mediates the assembly and disassembly of actin filaments, [19] [20] [21] (Figure 3b ). LIM-kinases (LIMK) and testis-specific protein kinases (TESKS) phosphorylate cofilin on a single serine residue (Ser 3) and phosphorylated cofilin (p-cofilin) is inactive to bind to filament-actin (F-actin), resulting in F-actin stabilization. Conversely, the Slingshot family phosphatases and PDXP (chronophin, pyridoxal phosphate phosphatase) reactivate cofilin by removal of phosphate from ser-3 residue. Cofilin binds to F-actin and mediates F-actin severing and depolymerization. We proceeded to investigate whether siRNA treatment of other genes in this pathway (PDXP, LIMK1, LIMK2 and CFL1) would have similar effects on SSH2 knockdown in FLCN-deficient cells. However, although knockdown of SSH1, LIMK1 and CFL1 induced about a two-fold increase in Caspase3/7 activity in UOK257-FLCN null cells, cell viability remained unchanged ( Figure 3c) .
Next, we investigated whether SSH2 knockdown in UOK257 cell lines might have differential effects on cofilin phosphorylation dependent on FLCN status. In normal physiological conditions, knockdown of phosphatases (SSH/PDXP) would increase cofilin phosphorylation, whereas knockdown of kinases (LIMK/TESK) would result in the reduction of cofilin phosphorylation (Figure 3d ). Western blot was carried out in UOK257 cells with/ without FLCN expression and p-cofilin was normalized by total cofilin whereas FLCN, SSH3 and LIMK1 proteins were normalized by actin for each siRNA treatment before being compared with luciferase siRNA control. In FLCN-expressing UOK257-2-FLCN þ cells, the expected increase in cofilin phosphorylation was detected (up to B400%) after knockdown of phosphatases (SSH1/2/3/PDXP) and treatment with LIMK1/2 siRNAs decreased cofilin phosphorylation (up to B40%, see Figure 3d ). However, in FLCN-null UOK257 cells no change or only slight increase (up to 150%) in cofilin phosphorylation was found after SSH/PDXP siRNAs treatment. In addition, UOK257-FLCN null cells demonstrated an increase in cofilin phosphorylation (B100%, in contrast to the expected reduction observed in UOK257-2-FLCN þ cells) after treatment with LIMK1/2 siRNAs. It is suggested that the absence of FLCN protein in UOK257 is associated with the altered regulation of cofilin de/phosphorylation pathways ( Figure 3b ). Interestingly, in UOK257-2-FLCN þ cells SSH1, SSH2 and PDXP siRNA-induced knockdown was associated with a decrease in FLCN expression (up to 60% decrease), whereas there is no SSH3 protein expression in FLCN-expressing UOK257 cells. SSH2 knockdown did increase SSH3 protein expression (five-fold) in UOK257-FLCN null cells, suggesting a compensatory regulatory mechanism among members of the SSH2 and SSH3 proteins. Owing to the lack of specificity for commercially available antibodies for SSH1 and SSH2, we were unable to determine whether SSH2 knockdown is altered expression of SSH1 protein or vice versa, though a compensatory relationship among SSH transcripts in FTC133 cells with/without FLCN expression was detected (Figure 3a) . It appeared that knockdown of phosphatases (SSH1/2/3 and PDXP) enhanced LIMK1 expression (up to B200%) whereas CFL1 knockdown decreased LIMK1 expression (up to B40%, Figure 3d ) irrespective of FLCN status in these cells.
Strikingly, in UOK257-FLCN null cells, strong activated Caspase3 bands (17 and 19 bands-indicating induction of Caspase3/7 activity) were detected only after treatment with SSH2 siRNA, whereas in UOK257-2-FLCN þ cells, much weaker Caspase3 activation was seen after knockdown of SSH1, SSH2, LIMK1/2 and CFL1. CFL1 siRNA treatment was used as a positive control for decreased expression of both p-cofilin and total cofilin in UOK257 cells irrespective of FLCN status.
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Examination of Caspase3/7 activity and cofilin expression after multiple SSH siRNA treatment In the light of the observation that SSH2 knockdown was accompanied by increases in SSH1/3 transcripts in FTC133 and in SSH3 protein in UOK257 cells (Figures 3a and d) , we examined whether multiple SSH siRNAs treatment could potentiate the effects of SSH2 knockdown in Caspase3/7 activity and cofilin phosphorylation. Both isogenic pairs of UOK257 and FTC133 cells with/without FLCN expression were incubated with ranges of SSH2 siRNAs, either alone, or in combination with SSH1 and/or SSH3 siRNAs, at 5 and 10 nM concentrations for 72 h before Caspase3/7 activity was measured. Luciferase siRNA was used as control. As shown in Figure 4a , in FLCN-null FTC133-12 and UOK257 cells, more induction of Caspase3/7 activities were observed (up to At the end of incubation, cell viability and Caspase3/7 activity were determined and compared with luciferase siRNA control. SSH2 and SSH3 (as numbered 14 and 16, respectively), were selected as potential positive hits in second round screen for their decrease in cell viability and induction of Caspase3/7 activity.
five-fold in FTC133-12 and seven-fold in UOK257 cells) after multiple SSHs knockdown (SSH2 þ 1 and SSH2 þ 1 þ 3) than those in SSH2 knockdown alone (2.5-fold in FTC133-12 and 4.5-fold in UOK257 cells). In FLCN-expressing FTC133-22 and UOK257-2 cells, a similar pattern can be seen at a much smaller degree (up to two-fold Caspase3/7 induction in multiple SSH siRNAs treatment).
Western analysis was performed to investigate cofilin phosphorylation status following knockdown of multiple SSHs in FTC133 cells with/without FLCN expression (Figure 4b ). In FTC133-22-FLCN þ cells, as expected p-cofilin was elevated (up to 65% in triple SSH1 þ 2 þ 3 knockdown, compared with Luciferase siRNA treatment) in almost all knockdown experiments with the exception for single SSH2 siRNA treatment in which p-cofilin Figure 2 . Exponentially growing UOK257 cells (a) and FTC133 cells (b) with/without FLCN expression were transfected with siRNAs at indicated concentrations for 72 h and Caspase3/7 activity and cell viability were then determined and compared with luciferase siRNA control. (c) UOK257 cells were transfected with siRNA at indicated concentrations and Caspase3/7 activity was measured at 24, 48 and 72 h and those from SSH2 siRNA were compared with luciferase siRNA control. (Figure 4b ). CFL1 siRNA was used as a positive control to knockdown cellular total cofilin and p-cofilin. After knockdown of cofilin, there was increased SSH3 protein expression in both FLCN-null and FLCN-expressing FTC133 cells, however, active Caspase3 was only induced in FLCN-null FTC133 cells (Figure 4b ).
Analysis of cell cycle changes in UOK-257 cells in response to single or multiple SSH siRNAs treatment To study the underlying mechanism of differential induction of Caspase3/7 activity after SSH2 knockdown, cell cycle analysis was performed in UOK257 cells with/without FLCN expression, using high content cytometry (Acumen Explorer). Cells were transfected with single siRNAs (Luciferase, SSH1, SSH2 and SSH3) or multiple siRNAs (SSH2 þ SSH1, SSH2 þ SSH3 and SSH2 þ SSH1 þ SSH3) at a range of concentrations (as indicated in Figure 5 ) for 72 h. The cell cycle populations at the same treatment but without siRNA were used as controls. In FLCN-null UOK257 cells, single SSH2 siRNA treatment elongated the G1 phase of the cell cycle (up to 20% increase) and shortened the S and G2M phases (30 and 40% decrease, respectively). This cell cycle change pattern was easily observed after SSH2 knockdown even in the lowest siRNA concentration (1 nM) examined. A similar, but less marked, pattern was found after SSH3 knockdown (10% increase in G1, 20% decrease in S and 10% decrease in G2M) in UOK257-FLCN null cells. No consistent cell cycle changes were detected after single SSH siRNA treatments in FLCN-expressing UOK257-2 cells ( Figure 5) .
In UOK257-FLCN null cells, multiple SSH siRNA treatment induced similar cell cycle changes to those seen after SSH2 knockdown with all three treatments, most prominently with the combinations of SSH2 þ SSH3, or SSH2 þ SSH1 þ SSH3 siRNAs (20% increase in G1, 40% decrease in both S and G2M phases, respectively). However, in UOK257-2-FLCN þ cells, similar, but less marked, changes in cell cycle kinetics (up to 20% increase in G1 phase, 20% decrease in both S and G2M phases, respectively) were found only Caspase3/7 activity and cell viability assays were performed and compared with luciferase siRNA controls as before. After SSH1 siRNA treatment, there was increased Caspase3/7 activity (100% Figure 5 . UOK257-FLCN null or UOK257-2-FLCN þ cells were transfected with either single siRNA or in combination of multiple siRNAs at indicated concentrations for 72 h. Cells were then fixed and stained with propidium iodide before being scanned with the Acumen eX3 cytometer and the percentage of each cell cycle population was calculated and normalized by zero siRNA control. Figure 6a ). Although reductions in cell viability were detected after SSH3 siRNA transfection, this was not associated with Caspase 3/7 induction in KTCL26. For SSH2 siRNA treatment, similar levels of Caspase3/7 induction to those in FTC133-12 cells were observed in 786-0 and KTCL26 (up to three-fold, 20 nM), although the degree of reduction in cell viability in these two cell lines were less than those in FTC133-12, which reached 50% reduction at 5 nM. In order to examine whether there is a relationship between expression levels of cellular FLCN and three members of Slingshot family, basal levels of FLCN and SSH1/2/3 transcripts were determined by real-time PCR in UOK257, UOK257-2, FTC133-12 and FTC133-22 cells, and in two RCC cell lines (786-0 and KTCL26). Each gene was measured at least three times and normalized by GAPDH before being compared with those expressed in UOK257 cells. As shown in Figure 6b , there was differential expression of FLCN transcripts between isogenic cells UOK257 and UOK257-2, and between FTC133-12 and FTC133-22 (2.5-and 4-fold, respectively). Endogenous FLCN transcripts in two RCC (786-0 and KTCL26) were expressed at similar range as FTC133-22. It is interesting to note that elevated expression in SSH1 transcripts was associated with FLCN expression in both UOK257 and FTC133 cells, however, ratios (FLCN-null vs. FLCNexpressing) of SSH2 and SSH3 transcripts showed discrepancy in the two pairs of isogenic cells. As SSH3 protein is not expressed in UOK257-2 cells (Figure 3d ), SSH3 transcripts were also found to be nearly three-fold lower than its counterpart UOK257 cells. In ACHN RCC cells, knockdown of endogenous FLCN (seven-fold lower) was accompanied by reduced SSH1 (greater than two-fold decrease) and elevated SSH3 transcripts (two-fold increase, data not shown), suggesting a similar phenomenon to those seen in RCC UOK257 cells.
DISCUSSION
After undertaking a phosphatase siRNA library screen in FLCN-null UOK257 cells, we identified Slingshot 2 serine phosphatase (SSH2) as a candidate synthetic lethal gene for FLCN. Knockdown of SSH2 preferentially induced activation of Caspase3/7 in the FLCN-null UOK257 RCC cell line (derived from a patient with BHD syndrome) and the FLCN-null thyroid carcinoma FTC133-12 cell line compared with their FLCN-expressing UOK257-2 and FTC133-22 counterparts. In contrast, knockdown of the other two members of Slingshot family SSH1 and SSH3 did not show similar pattern as seen with SSH2, although a compensatory regulation mechanism in transcripts and proteins was among members of SSH family (Figures 3a, d and 4b) . Furthermore, multiple knockdown of SSH1 or/and SSH3 potentiated SSH2 siRNA activity in both Caspase3/7 induction and cell cycle kinetics (G1 arrest, S and G2M shortening) in FLCN-null cells. These results indicated that activation of Caspase3/7 following siRNA-induced SSH2 knockdown is a specific event in FLCN-null UOK257 and FTC133-12 cells and not a general feature for Slingshot gene family (though knockdown of other SSHs can enhance the effects of SSH2 knockdown). Previously, we found that mithramycin preferentially induced Caspase3/7 activity in FLCN-deficient UOK257 cells but, in contrast to SSH2 knockdown, no preferential effect was apparent in FLCN-deficient FTC133. Although SSH2 siRNA treatment induced cell cycle changes (G1 arrest, S and G2M shortening) in FLCN-null UOK257 cells ( Figure 5 ), treatment with mithramycin resulted in a different pattern of cell cycle changes (increases in population and elongation time in G2M cell phase. 22 Both UOK257 and FTC133 cells contain p53 mutations, 22 suggesting that induction of Caspase3/7 activation by SSH2 knockdown is mediated by a p53-independent cell death pathway.
Slingshot phosphatases and LIM-kinases are involved in activation/stabilization of filament-actin through cofilin de/ phosphorylation. We found evidence that cofilin de/phosphorylation is different or dysregulated in cells deficient in folliculin, but can be recovered partly (FTC133-22) or fully (UOK257-2) in their folliculin-expressing counterparts. To date, folliculin function has not been linked to actin cytoskeleton function, but we note that siRNA knockdown of regulators for cofilin phosphorylation status (SSH1/2 and PDXP phosphatases) can be associated with decreased expression in FLCN protein and transcript in the cells examined (Figures 3d and 4b , and data not shown). Interestingly, there is an inverse expression pattern between FLCN and SSH3 proteins and transcripts in UOK257 and ACHN cells (Figures 3d  and 6b, data not shown) . In addition, expression of FLCN was associated with elevation of SSH1 transcripts in three pairs of FLCN isogenic cell lines (UOK257, FTC133 and ACHN FLCN knockdown, Figure 6b and data not shown). FLCN might act as a modulator in balance of cellular expression levels for the members of Slingshot family in the cells, either in transcriptional levels (for example, trans-repression of SSH3 and trans-activation of SSH1) or protein levels (for example, enhancement of SSH3 ubiquitin degradation). Although no clear relationship was found between basal levels of FLCN and SSH2 in the cells examined, knockdown of SSH2 (and other Slingshots) was accompanied with down-expression of FLCN protein and transcripts. Folliculin-deficient cells might be preferentially sensitive to SSH2 knockdown due to dysregulation of Slingshot family members as well as abnormal actin function. Cofilin has been reported to have diverse functions including modulation of actin dynamics, release of cytochrome c and Bax translocation to mitochondria during excitotoxic neuronal death 23, 24 but it is possible that the functional relationship between folliculin, SSH2 and cell death might relate to cofilin-independent functions of SSH2.
Human cancers represent a heterogeneous groups of disorders associated with the activation of oncogenes and inactivation of TSGs. In general, the development of targeted therapies for cancer by correction of TSG inactivation is generally more challenging than targeting oncogene activation. Nevertheless, the identification of synthetic lethal interactions can present a tractable approach to developing novel targeted therapies for kidney cancer, [25] [26] [27] as exemplified for BRCA1/2, 28 and p53. 29 Thus, the identification, through a phosphatase siRNA library screen, of SSH2 as a candidate synthetic lethality target for FLCN-deficient cells suggests that the development of small molecular weight compounds for targeting SSH2 phosphatase activity could provide a strategy for developing novel molecular targeted drugs for BHD syndrome and possibly for some sporadic RCCs. FTC133 cells, originally derived from a lymph node metastasis of a follicular thyroid carcinoma from a 42-year-old male, were purchased from ECACC (Salisbury, United Kingdom) and a FLCN-containing construct and an empty vector were introduced into parental FTC133 cells respectively and stably transfected cells with/without FLCN expression were selected with neomycin. 22 All cell lines including renal carcinoma cell lines 786-0 and KTCL26 were cultured in DMEM with supplement of 10% fetal bovine serum except for FTC133 cells, which were incubated in medium containing DMEM and Ham's F12 (1:1).
MATERIALS AND METHODS

Cell lines and reagents
Phosphatase siRNA library screening and cell viability assay Cell viability of the UOK257-FLCN null cells in response to the treatment of phosphatase siRNA was compared with those of luciferase control siRNA using CellTiter-Blue Cell Viability Assay (Promega, Southampton, UK) as described previously. 22 Any reduction in the ratio of cell viability from phosphatase siRNA vs luciferase siRNA (o0.9) was selected as potential hits. Briefly, diluted siRNA (Silencer Select human Phosphatase siRNA Library, Ambion, Warrington, UK) was mixed with transfection reagent (INTERFERin, Polyplus Transfection, Hampshire, UK) at a final volume of 10 ml in a 96-well plate before adding exponentially growing cells (6 Â 10 3 cells/90 ml/well). The final siRNA library screening concentration was at 20 nM. After siRNA transfected for 72 h, the cells were incubated with 20 ml of CellTiter-Blue Cell Viability Assay reagent for an additional 4 h. The cell viability was measured by fluorescence with a 570 nm excitation and 590 nm emission set in a Victor X3 Multilabel Plate Reader (PerkinElmer, Beaconsfield, UK).
Caspase-Glo 3/7 assay
The ability to induce Caspase3/7 activation after exposure to siRNA was measured by Caspase-Glo 3/7 Assay (Promega) according to the manufacturer's instruction. The cells were added to siRNA/INTERFERin mixture as described in Phosphatase siRNA library screen. At the end of incubation, 50 ml of medium was removed and 50 ml of assay reagent was added to the remaining medium. Additional 1 hour incubation with shaking was carried out at room temperature. The resultant luminescent light was measured in a Victor X3 Multilabel Plate Reader (PerkinElmer, Beaconsfield, UK). 
Measurement of Gene Transcript Levels
Western blot analysis
Cellular protein expression in UOK257 and FTC133 cells in response to siRNA treatment was determined using total cell extracts at 72 h after treatment as described previously. 30 Protein concentration was determined using DC protein assay kit according to the manufacturer's instructions (Bio-Rad Laboratories Ltd). 20 mg of total protein from each sample was electrophoresed on 7.5 or 15% (w/v) SDS-PAGE gels and electroblotted on to nitrocellulose membrane (Amersham Pharmacia Biotech UK Ltd., Buckinghamshire, UK) before incubation against antibodies for FLCN, Caspase3, cofilin and p-cofilin (Cell Signalling Technology, Hertfordshire, UK), SSH3, LIMK1 (Novus Biologicals, Cambridge, UK) and actin (Sigma-Aldrich Company Ltd., Dorset, UK). The signal was detected using the enhanced chemiluminescence (ECL þ Plus, Amersham) system after addition of anti-mouse/rabbit IgG-HRP conjugate (Dako, Ely, UK). The intensity of individual protein band was quantified by ImageJ (a public domain, Java-based image processing program, National Institutes of Health) and actin protein was used as loading control. Protein expression levels from each siRNA treatment was normalized by those from Luciferase siRNA control.
Cell Cycle Analysis UOK-257 cells with/without FLCN expression were seeded at 2000 cells per well in 96-well plates and transfected either with single siRNAs or with multiple siRNAs at various concentrations (eight technical replicates) as indicated in the Results section, and incubated at 37 o C/5% CO2 for 72 h. At the end of the time course, media was carefully removed and cells were fixed in 85% ice-cold ethanol. After removal of ethanol, cells were incubated in the dark at 37 o C for 20 min in PBS buffers containing 0.1% Triton X-100, 100 mg/ml RNase A and 10 mg/ml propidium iodide (PI). The 96-well plates were subsequently scanned using the Acumen eX3 cytometer (TTP LabTech, Melbourn, Royston, UK). The relative percentages of G1, S and G2M cell cycle phases in each treatment were calculated and normalized to those with zero siRNA control.
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